| Customization: | Available |
|---|---|
| Application: | Internal Medicine |
| Usage Mode: | For oral administration |
|
Still deciding? Get samples of US$ 1/box
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Name | Gabapentin capsules |
| Dosage form | Capsule |
| Adaptation disease | 1. Post-herpetic neuralgia: used for the treatment of post-herpetic neuralgia in adults. 2. Epilepsy: Adjunctive therapy for partial seizures in adults and children over 12 years of age with or without secondary systemic seizures. It can also be used for the adjunctive treatment of partial seizures in children aged 3 ~ 12 years. |
| Character | The content of this product is white or quasi-white powder or particles. |
| Strenth | (1)100mg; (2) 300mg; |
| Usage and dosage | 1. Adult neuralgia after herpes infection: one dose of 0.3g gabapentin on the first day, 0.6g on the second day, divided into two doses; On the third day, take 0.9g in three doses. The dose can then be gradually increased to 1.8g per day in three doses, depending on the need for pain relief. In foreign clinical studies, the efficacy was comparable in the 1.8g to 3.6g daily dose range, and no additional benefit was shown at doses above 1.8g daily. 2. Epilepsy: Gabapentin may be used in combination with other antiepileptic drugs. Gabapentin is administered orally in divided doses (3 times daily). The method of administration is gradually increased from an initial low dose to an effective dose. Patients over 12 years old: 0.3g each time, once a day, on the first day of administration; On the second day, 0.3g, twice a day, on the third day, 0.3g, three times a day, and then maintain the same dose. According to foreign literature, the dosage of gabapentin can be increased to 1.8g per day, and some patients can tolerate the dosage up to 2.4g per day. The safety of doses beyond 2.4g/day is uncertain. Pediatric patients aged 3 to 12 years: the initial dose should be 10 to 15mg/kg/d, 3 times daily, reaching an effective dose in approximately 3 days. The effective dose of gabapentin is 25 to 35mg/kg/d, three times daily, in patients over 5 years of age. The effective dose for pediatric patients aged 3 to 4 years is 40mg/kg/d, three times daily. If necessary, the dose can be increased to 50mg/kg/d. Long-term clinical studies have shown that doses up to 50mg/kg/d are well tolerated. The maximum interval between doses should not exceed 12 hours. In order to reduce the occurrence of dizziness, drowsiness and other adverse reactions, the first day of medication can be taken before going to bed. There is no need to monitor gabapentin blood concentration during gabapentin administration. Moreover, since gabapentin has no significant pharmacokinetic interaction with other conventional antiepileptics, combination therapy with gabapentin does not alter the plasma concentration of these conventional antiepileptics. Discontinuation of gabapentin or the introduction of a new regimen should be phased in gradually for at least one week during treatment. Creatinine clearance is difficult to measure in outpatients. Creatinine clearance (CCr) in patients with stable renal function can be reasonably estimated based on Cockcroft and Gault's equation: Female CCr =(0.85)(140-age)(weight)/[(72)(SCr)] Male CCr =(140-age)(weight)/[(72)(SCr)] where the age unit is years, the weight unit is kg,SCr is serum creatinine, the unit is mg/dL. The following dose adjustments are recommended for patients over 12 years of age with renal impairment or undergoing hemodialysis: Table 1. Adjustment of gabapentin dose according to patients' renal function a. Administration on alternate days. B. Patients who did not receive gabapentin received an initial dose of 0.3 to 0.4g, followed by 0.2 to 0.3g of gabapentin every 4 hours of dialysis. No studies have been conducted on gabapentin in patients under 12 years of age with renal impairment. Dosing in elderly patients: Because elderly patients are likely to have reduced renal function, dosing should be carefully selected and should be adjusted for creatinine clearance in these patients. |
| Storage | seal preservation |
| Origin | China |
| Validity | 24 months |
){kind=link}